NDA 207926 · Alcon
Phenylephrine Hydrochloride
Phenylephrine Hydrochloride · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Mar 13, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jan 15, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
627
74 Phase 3, 25 recruiting
FAERS reports
3,598
3,445 serious, 1,812 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 1, 2025.
Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10%, is indicated to dilate the pupil. Phenylephrine Hydrochloride Ophthalmic Solution is an alpha-1 adrenergic receptor agonist indicated to dilate the pupil ( 1 )
Mechanism: Phenylephrine hydrochloride is an α-1 adrenergic agonist drug that is used in ophthalmology mainly for its mydriatic effect. After topical application to the conjunctiva, phenylephrine acts directly on α-adrenergic receptors in the eye, producing contraction of the dilator muscle of the pupil and constriction of the arterioles in the conjunctiva.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 15, 2015 Original approval · Type 7 - Drug Already Marketed without Approved NDA ReviewLetterLabel
2 products under this application
- PHENYLEPHRINE HYDROCHLORIDE · PHENYLEPHRINE HYDROCHLORIDE 2.5% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
- PHENYLEPHRINE HYDROCHLORIDE · PHENYLEPHRINE HYDROCHLORIDE 10% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Phenylephrine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac SurgeryPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06802224 · 18,000 participants (planned) · Start Apr 1, 2025 · Primary completion Jul 2028
Drug: Norepinephrine; Phenylephrine · For: Anesthesia; Surgery With General Anesthesia; Noncardiac Surgery and 4 more
Sites: San Francisco, California; College Park, Maryland; Ann Arbor, Michigan · 10 sites in all
- The GUARDIAN Trial - Vasopressor Sub-StudyPivotal-lookingEnrolling by invitation
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT04934748 · 6,254 participants (planned) · Start Jul 25, 2021 · Primary completion Dec 31, 2026
Drug: Phenylephrine; Norepinephrine · For: Blood Pressure
Sites: Omaha, Nebraska; Cleveland, Ohio; Beijing, China · 11 sites in all
- Norepinephrine vs Phenylephrine During General AnesthesiaPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT04789330 · 3,626 participants · Start Jul 1, 2021 · Primary completion Apr 1, 2022
Drug: Norepinephrine; Phenylephrine · For: Anesthesia; Surgery; Hypotension
Sites: Los Angeles, California; San Francisco, California · 5 sites in all
- Target Hemodynamics and Brain Injury During General Anesthesia in the ElderlyPivotal-lookingSuspended
Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoAcademic, hospital or other
NCT02428062 · 1,812 participants (planned) · Start Oct 2014 · Primary completion Dec 2018
Drug: Phenylephrine; Intravenous fluids and 4 more · For: Post-operative Cognitive Dysfunction
Sites: Milan, Italy
- OB VEGA-Phenylephrine vs Norepinephrine OutcomesPivotal-lookingNot yet recruiting
Wake Forest University Health SciencesAcademic, hospital or other
NCT07900919 · 1,500 participants (planned) · Start Jan 2027 · Primary completion Dec 2027
Drug: Phenylephrine; Norepinephrine · For: Hypotension During Surgery; Cesarean Birth
Sites: Winston-Salem, North Carolina
- Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac SurgeryPivotal-lookingRecruiting
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT05635227 · 1,200 participants (planned) · Start Nov 10, 2022 · Primary completion Dec 2027
Drug: Dexamethasone phosphate; Isotonic sodium chloride (0.9%) and 2 more · For: Coronary Artery Disease; Aortic Valve Disease
Sites: Copenhagen, Denmark
- Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-GrowthPivotal-lookingNot yet recruiting
Applied Biology, Inc.Industry
NCT06648850 · 1,120 participants (planned) · Start May 1, 2026 · Primary completion Mar 19, 2027
Drug: DA-001; Phenylephrine and 1 more · For: Telogen Effluvium; Female Pattern Hair Loss; Female Pattern Hair Loss, Androgenic Alopecia and 3 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,363
- pemphigus1,074
- joint swelling1,038
- pain1,004
- maternal exposure during pregnancy1,003
- infusion related reaction996
- glossodynia995
- rheumatoid arthritis993
- drug ineffective984
- pericarditis983
- systemic lupus erythematosus981
- wound966
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 14 |
| 2006 | 6 |
| 2007 | 15 |
| 2008 | 15 |
| 2009 | 8 |
| 2010 | 43 |
| 2011 | 18 |
| 2012 | 52 |
| 2013 | 29 |
| 2014 | 16 |
| 2015 | 27 |
| 2016 | 28 |
| 2017 | 46 |
| 2018 | 46 |
| 2019 | 61 |
| 2020 | 109 |
| 2021 | 123 |
| 2022 | 267 |
| 2023 | 318 |
| 2024 | 976 |
| 2025 | 995 |
| 2026 | 384 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Thymoxamine reverses phenylephrine-induced mydriasis.
Relf SJ, Gharagozloo NZ, Skuta GL, et al. · Am J Ophthalmol 1988 · Clinical Trial, Randomized Controlled Trial
- Testing individual baroreflex responses to hypoxia-induced peripheral chemoreflex stimulation.
Kronsbein H, Gerlach DA, Heusser K, et al. · Clin Auton Res 2020 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Efficacy and safety of oral phenylephrine: systematic review and meta-analysis.
Hatton RC, Winterstein AG, McKelvey RP, et al. · Ann Pharmacother 2007 · Meta-Analysis, Systematic Review
- Cardiovascular Adverse Effects of Phenylephrine Eyedrops: A Systematic Review and Meta-analysis.
Stavert B, McGuinness MB, Harper CA, et al. · JAMA Ophthalmol 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- The safety of intracameral phenylephrine - A systematic review.
Gowda A, Jie WWJ, Casson R, et al. · Surv Ophthalmol 2022 · Systematic Review
- Norepinephrine vs. phenylephrine for spinal hypotension in cesarean section: a network meta-analysis.
Imai E, Kataoka Y, Watanabe J, et al. · J Anesth 2025 · Systematic Review, Comparative Study
Sponsor: Alcon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.